Oragenics to Showcase Concussion Drug ONP-002 at Investor Summit 2026
January 14, 2026 — Oragenics announces presentation at Sequire Investor Summit 2026 to highlight ONP-002, a novel intranasal treatment for concussion and mild traumatic brain injury.